SCHEMBL24590407

SCHEMBL24590407

CNc1ccc(N2CCC(C)CC2)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ NPC1 O15118 4/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ TSHR P16473 3/20 0.45
▸ LMNA P02545 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PKM P14618 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41
▸ AR P10275 1/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ DGAT1 O75907 1/20 0.40
▸ DDB1 Q16531 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26739731 0.91 MAPT (0.46) MAPTNPC1RAB9AALDH1A1TSHR
SCHEMBL24590136 0.83 MAPT (0.51) MAPTNPC1RAB9AALDH1A1TSHR
SCHEMBL24590235 0.83 MAPT (0.51) MAPTNPC1RAB9AALDH1A1TSHR
SCHEMBL26739746 0.83 MAPT (0.45) MAPTRAB9AALDH1A1LMNAPKM
SCHEMBL4082936 0.83 KCNQ3 (0.48) MAPTRAB9AALDH1A1LMNAKDM4E
SCHEMBL13006763 0.81 MAPT (0.49) MAPTALDH1A1LMNAKDM4EGAA
SCHEMBL12845203 0.80 RAB9A (0.57) MAPTRAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL22755219 0.80 MAPT (0.57) MAPTNPC1RAB9AALDH1A1TSHR
SCHEMBL23446016 0.79 CNR2 (0.46) MAPTNPC1RAB9AALDH1A1LMNA
SCHEMBL2790485 0.79 MAPT (0.58) MAPTNPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME TPX2, AIMP2, CDYL2 MAPT 4461/4885NPC1 1722/4885RAB9A 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback